Artiva Biotherapeutics (NASDAQ:ARTV) Director Acquires $74,999,992.32 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. acquired 6,510,416 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of $11.52 per share, for a total transaction of $74,999,992.32. Following the completion of the transaction, the director directly owned 15,203,995 shares of the company’s stock, valued at $175,150,022.40. The trade was a 74.89% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Artiva Biotherapeutics Stock Performance

ARTV stock opened at $9.78 on Friday. Artiva Biotherapeutics, Inc. has a fifty-two week low of $1.47 and a fifty-two week high of $14.53. The business’s 50-day moving average is $8.19 and its two-hundred day moving average is $5.58. The company has a market cap of $241.76 million, a price-to-earnings ratio of -2.76 and a beta of 2.86.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). Equities analysts predict that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on ARTV shares. HC Wainwright lifted their target price on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Wall Street Zen raised Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Needham & Company LLC lifted their target price on Artiva Biotherapeutics from $18.00 to $41.00 and gave the company a “buy” rating in a research note on Tuesday. Wedbush lifted their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Artiva Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

Hedge Funds Weigh In On Artiva Biotherapeutics

Institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its holdings in Artiva Biotherapeutics by 14,463.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after buying an additional 117,733 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Artiva Biotherapeutics in the 4th quarter worth approximately $174,000. Landscape Capital Management L.L.C. purchased a new position in shares of Artiva Biotherapeutics in the 3rd quarter worth approximately $112,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Artiva Biotherapeutics in the 4th quarter worth approximately $91,000. Finally, Marshall Wace LLP purchased a new position in shares of Artiva Biotherapeutics in the 2nd quarter worth approximately $79,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.